SMFM Reaffirms Support for Patient Access to Comprehensive Reproductive Healthcare

In light of recent actions by the Trump administration regarding the Emergency Medical Treatment and Labor Act (EMTALA) and mifepristone, the Society for Maternal-Fetal Medicine (SMFM) reaffirms its support for policies that allow maternal-fetal medicine physicians and other clinicians to provide evidence-based, medically appropriate treatment to their patients. Policy decisions about medical care during pregnancy, including abortion care, should be based on objective, peer-reviewed scientific evidence. 

Although the Trump administration’s actions introduce unnecessary confusion and apprehension among clinicians, hospitals, and the public, it is important to remember that EMTALA, the federal law requiring hospitals to treat and stabilize anyone who presents with an emergency medical condition, remains in effect, and that mifepristone remains safe, effective, and FDA-approved for medication abortion care.  

Every person deserves access to the full spectrum of reproductive healthcare, including abortion care. As the organization representing specialists in high-risk pregnancy, SMFM is dedicated to ensuring every person gets the care they need and the outcome that is best for them and their pregnancy. 

#  #  # 

About SMFM 
The Society for Maternal-Fetal Medicine (SMFM), founded in 1977, is the medical professional society for obstetricians who have additional training in high-risk, complicated pregnancies. SMFM represents more than 6,500 members who care for high-risk pregnant people and provides education, promotes research, and engages in advocacy to reduce disparities and optimize the health of high-risk pregnant people and their families. SMFM and its members are dedicated to optimizing maternal and fetal outcomes and assuring medically appropriate treatment options are available to all patients. 

Contact: Greg Phillips, Director of Communications, press@smfm.org